2 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 3 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Not applicable | 1 | Recruiting 1 |
Follow NonHodgkin Lymphoma: new trials by email Literature Review of NonHodgkin Lymphoma trials Research Report on NonHodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma TAS4464 - Multiple Myeloma, NonHodgkin Lymphoma | Phase 1 | Terminated | Taiho Oncology, Inc. | 11 | 2017-03-01 | 2024-09-05 |
| A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) Evorpacept (ALX148), Pembrolizumab, Trastuzumab - Metastatic Cancer, Solid Tumor | Phase 1 | Completed | ALX Oncology Inc. | 174 | 2017-02-03 | 2025-08-01 |
| Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma. Standard Arm, Experimental Arm - NonHodgkin Lymphoma | Not applicable | Recruiting | Tata Memorial Hospital | 840 | 2016-11-01 | 2025-04-11 |
| HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life Breast Cancer Female, Breast Neoplasm | Unknown | University Hospital Southampton NHS Foundation Trust | 3000 | 2016-08-01 | 2021-03-17 | |
| Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) EBVST Cells, Nivolumab - NonHodgkin Lymphoma, Lymphoproliferative Disorders | Phase 1 | Completed | Baylor College of Medicine | 8 | 2016-02-16 | 2021-07-21 |
| Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia | Active not recruiting | National Cancer Institute (NCI) | 1836 | 2002-07-08 | 2026-10-13 |
Lymphoma, Non-Hodgkin (6) · Neoplasms (3) · Hodgkin Disease (2) · Lymphoma (2) · Lymphoma, Large B-Cell, Diffuse (2) · Breast Neoplasms (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, T-Cell, Peripheral (1) · Lymphoproliferative Disorders (1)
Hemic and Lymphatic Diseases (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Neoplasms by Histologic Type (6) · Lymphoproliferative Disorders (5) · Lymphoma (4) · Neoplasms (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Disease Attributes (2) · Hemorrhagic Disorders (2) · Hemostatic Disorders (2)
ALX148 (1) · Cisplatin (1) · Fluorouracil (1) · Nivolumab (1) · Paclitaxel (1) · Ramucirumab (1) · Rituximab (1) · TAS4464 (1) · Trastuzumab (1) · pembrolizumab (1)
ALX Oncology Inc. (1) · Baylor College of Medicine (1) · National Cancer Institute (NCI) (1) · Taiho Oncology, Inc. (1) · Tata Memorial Hospital (1) · University Hospital Southampton NHS Foundation Trust (1)
United States (4) · India (1) · South Korea (1) · United Kingdom (1)
Douglas R Stewart, M.D. (1) · Jayant Sastri Goda, M.D (1) · Ravi Pingali, MD (1)